XML 37 R25.htm IDEA: XBRL DOCUMENT v3.22.4

Revenue (Tables)

12 Months Ended

Dec. 31, 2022

Revenue

Net revenue initiated sales in the United States of total net revenue

​

​	​	​	​	​	​	​	​	​	​
​	​	Year Ended December 31,
(in thousands)		2022		​	2021		​	2020
Products	​	​	​	​	​	​	​	​	​
UDENYCA	​	$	203,814	​	$	326,509	​	$	475,824
CIMERLI	​	​	6,946	​	​	—	​	​	—
Total net product revenue	​	​	210,760	​	​	326,509	​	​	475,824
Other	​		282	​		42	​		—
Total net revenue	​	$	211,042	​	$	326,551	​	$	475,824

​

Gross Revenues by Significant Customer as a Percentage of Total Gross Revenues

​

​	​	​	​	​	​	​	​	​	​
​	​	Year Ended December 31,
​	​	2022	​	​	2021		​	2020
McKesson Corporation	​	38	%	​	39	%	​	38	%
AmeriSource-Bergen Corporation	​	44	%	​	39	%	​	37	%
Cardinal Health, Inc.	​	17	%	​	20	%	​	23	%

​

Activities and Ending Reserve Balances for Each Significant Category of Discounts and Allowances

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Year Ended December 31, 2022

​

Chargebacks

​

​

Other Fees,

​

​

​

​

and Discounts

​

​

​

​

Co-pay

​

​

​

​

​

for Prompt

​

​

​

​

Assistance

​

​

​

(in thousands)

​

Payment

​

Rebates

​

and Returns

​

Total

Balances at December 31, 2021

​

$

29,665

​

$

54,004

​

$

26,054

​

$

109,723

Provision related to sales made in:

​

​

​

​

​

​

​

​

​

​

​

Current period

​

​

436,865

​

​

68,399

​

​

73,435

​

​

578,699

Prior period

​

​

(2,090)

​

​

(1,050)

​

​

32

​

​

(3,108)

Payments and customer credits issued

​

(421,763)

​

​

(82,640)

​

​

(80,408)

​

​

(584,811)

Balances at December 31, 2022

​

$

42,677

​

$

38,713

​

$

19,113

​

$

100,503

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Year Ended December 31, 2021

​

Chargebacks

​

​

Other Fees,

​

​

​

​

and Discounts

​

​

​

​

Co-pay

​

​

​

​

​

for Prompt

​

​

​

​

Assistance

​

​

​

(in thousands)

​

Payment

​

Rebates

​

and Returns

​

Total

Balances at December 31, 2020

​

$

40,580

​

$

54,058

​

$

28,760

​

$

123,398

Provision related to sales made in:

​

​

​

​

​

​

​

​

​

​

​

​

Current period

​

470,791

​

​

113,705

​

​

94,703

​

​

679,199

Prior period

​

​

(2,876)

​

​

(4,976)

​

​

(3,555)

​

​

(11,407)

Payments and customer credits issued

​

(478,830)

​

(108,783)

​

(93,854)

​

(681,467)

Balances at December 31, 2021

​

$

29,665

​

$

54,004

​

$

26,054

​

$

109,723

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Year Ended December 31, 2020

Balances at December 31, 2019

​

$

35,159

​

$

27,494

​

$

24,494

​

$

87,147

Provision related to sales made in:

​

​

​

​

​

​

​

​

​

​

​

​

Current period

​

462,328

​

​

115,864

​

​

114,372

​

​

692,564

Prior period

​

​

(1,336)

​

​

(3,438)

​

​

(6,288)

​

​

(11,062)

Payments and customer credits issued

​

(455,571)

​

(85,862)

​

(103,818)

​

(645,251)

Balances at December 31, 2020

​

$

40,580

​

$

54,058

​

$

28,760

​

$

123,398

​

X

- Definition

Schedule of product sales discounts and allowances.

+ References

No definition available.

+ Details

Name:	chrs_ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock
Namespace Prefix:	chrs_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 16
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592

+ Details

Name:	us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration